Disease-focused biomedical research institute with genomics and cell therapy focus
Gladstone runs three disease-focused institutes centered on cardiovascular, neurodegenerative, and infectious disease research. The tech stack reflects a wet-lab-first operation—Sanger sequencing, PacBio, Illumina, and imaging tools dominate—paired with computational depth in Python, PyTorch, R, and MATLAB for genomics analysis and modeling. Active projects span T-cell therapies, genome editing, viral evolution, and therapeutic vaccine development. Pain points cluster around financial forecasting and budget integration, not technical debt, suggesting research operations (not engineering) is the constraint.
Gladstone Institutes is a nonprofit biomedical research organization headquartered in San Francisco and founded in 1979. The organization operates three disease-focused institutes investigating cardiovascular disease, neurodegenerative conditions (including Alzheimer's and neurological disorders), and infectious diseases (HIV, AIDS, virology). Research activities combine classical molecular and cellular biology techniques with emerging computational approaches including genome editing, cell engineering, and computational virology. The workforce of 201–500 is research-heavy, with most open positions in lab-based roles and emerging hiring in data science and computational support. Funding and financial forecasting remain ongoing operational challenges.
Three disease-focused institutes investigating cardiovascular disease, neurodegenerative disorders (Alzheimer's, epilepsy, neurological conditions), and infectious diseases (HIV, AIDS, virology). Active projects include T-cell therapies, genome editing, viral biomarker detection, and vaccine development.
Wet-lab tools: Sanger sequencing, PacBio, Illumina. Computational: Python, PyTorch, R, MATLAB, Bash, ImageJ, Prism, SPSS. Stack reflects genomics analysis, statistical modeling, and computational biology workflows.
Other companies in the same industry, closest in size